CN1020752C - 后天性免疫缺乏综合征(爱滋病)疫苗 - Google Patents

后天性免疫缺乏综合征(爱滋病)疫苗 Download PDF

Info

Publication number
CN1020752C
CN1020752C CN86106632A CN86106632A CN1020752C CN 1020752 C CN1020752 C CN 1020752C CN 86106632 A CN86106632 A CN 86106632A CN 86106632 A CN86106632 A CN 86106632A CN 1020752 C CN1020752 C CN 1020752C
Authority
CN
China
Prior art keywords
lav
htlviii
recombinant
virus
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN86106632A
Other languages
English (en)
Chinese (zh)
Other versions
CN86106632A (zh
Inventor
胡水洛克
安东尼F·波居欧
林达·梅迪逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Original Assignee
Oncogen LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen LP filed Critical Oncogen LP
Publication of CN86106632A publication Critical patent/CN86106632A/zh
Application granted granted Critical
Publication of CN1020752C publication Critical patent/CN1020752C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN86106632A 1985-09-25 1986-09-25 后天性免疫缺乏综合征(爱滋病)疫苗 Expired - Fee Related CN1020752C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US77990985A 1985-09-25 1985-09-25
US779909 1985-09-25
US84298486A 1986-03-27 1986-03-27
US842984 1986-03-27
US90521786A 1986-09-09 1986-09-09
US905217 1986-09-09

Publications (2)

Publication Number Publication Date
CN86106632A CN86106632A (zh) 1987-05-13
CN1020752C true CN1020752C (zh) 1993-05-19

Family

ID=27419757

Family Applications (1)

Application Number Title Priority Date Filing Date
CN86106632A Expired - Fee Related CN1020752C (zh) 1985-09-25 1986-09-25 后天性免疫缺乏综合征(爱滋病)疫苗

Country Status (22)

Country Link
CN (1) CN1020752C (cg-RX-API-DMAC10.html)
AT (1) ATA256786A (cg-RX-API-DMAC10.html)
CH (1) CH676247A5 (cg-RX-API-DMAC10.html)
DE (1) DE3690508T1 (cg-RX-API-DMAC10.html)
DK (1) DK455486A (cg-RX-API-DMAC10.html)
ES (2) ES2002490A6 (cg-RX-API-DMAC10.html)
FI (1) FI863848A7 (cg-RX-API-DMAC10.html)
FR (1) FR2587720A2 (cg-RX-API-DMAC10.html)
GB (1) GB2181435B (cg-RX-API-DMAC10.html)
GR (1) GR862412B (cg-RX-API-DMAC10.html)
HU (1) HU205780B (cg-RX-API-DMAC10.html)
IE (1) IE59314B1 (cg-RX-API-DMAC10.html)
IL (1) IL80073A (cg-RX-API-DMAC10.html)
IT (1) IT1195829B (cg-RX-API-DMAC10.html)
MY (1) MY103182A (cg-RX-API-DMAC10.html)
NL (1) NL8602422A (cg-RX-API-DMAC10.html)
NO (1) NO863803L (cg-RX-API-DMAC10.html)
NZ (1) NZ217645A (cg-RX-API-DMAC10.html)
PT (1) PT83434B (cg-RX-API-DMAC10.html)
SE (4) SE8604007L (cg-RX-API-DMAC10.html)
WO (1) WO1987002038A1 (cg-RX-API-DMAC10.html)
YU (1) YU46753B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1105015C (zh) * 1995-09-06 2003-04-09 库夫施泰因模板技术股份公司 网板印刷模板的制备方法

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0220234B1 (en) * 1985-04-08 1994-08-03 Genetic Systems Corporation EXPRESSION AND DIAGNOSTIC USE OF gag ENCODED PEPTIDES WHICH ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO LAV
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
EP0260714B1 (en) * 1986-09-19 1994-06-29 Oncogen Limited Partnership The use of activated t-lymphocytes for preparing a pharmaceutical composition for the treatment of AIDS
IL84154A0 (en) * 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
JPS63258575A (ja) * 1986-12-15 1988-10-26 レプリゲン　コーポレーション 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク
JP2948823B2 (ja) * 1987-01-16 1999-09-13 アンステイテユ・パストウール ヒト免疫不全レトロウィルス（ｈｉｖ）関連抗原性ペプチド、そのウィルス感染の検出及びワクチンへの使用
FR2610632B1 (fr) * 1987-02-11 1990-12-21 Pasteur Institut Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
GB8714802D0 (en) * 1987-06-24 1987-07-29 Proteus Biotech Ltd Synthetic polypeptides
DE10399031I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
FR2620030B1 (fr) * 1987-09-07 1990-03-23 Transgene Sa Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
DE68917520T2 (de) * 1988-05-06 1995-01-05 Ferropas Ag Verfahren und Systeme zur Herstellung von HIV-Antigenen.
US5043262A (en) * 1988-05-12 1991-08-27 Dana Farber Cancer Institute Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
AP129A (en) * 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
ATE160377T1 (de) * 1989-04-18 1997-12-15 Applied Biotechnology Inc Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren
ES2198400T3 (es) * 1989-06-01 2004-02-01 Applied Biotechnology, Inc. Vector que codifica particulas virales no autopropagantes, defectuosas, auto-ensambladas.
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
FR2676068B1 (fr) * 1991-05-02 1994-11-04 Pasteur Institut Souches recombinantes immunogenes de b. anthracis - compositions immunogenes les contenant.
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
AU672372B2 (en) * 1991-11-08 1996-10-03 Pharmacia & Upjohn Company Feline leukemia virus vaccines
AU688283B2 (en) 1992-09-29 1998-03-12 Novartis Ag Pulmonary delivery of active fragments of parathyroid hormone
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
EP2036541A1 (en) 1994-03-07 2009-03-18 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
CA2212682A1 (en) 1995-02-10 1996-08-15 Worcester Foundation For Experimental Biology, Inc. Delivery of exogenous compounds
US6013506A (en) * 1995-06-05 2000-01-11 Wardley; Richard C. Feline leukemia virus vaccines
US6723558B1 (en) 1996-01-23 2004-04-20 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
SI1458360T1 (sl) 2001-12-19 2011-08-31 Novartis Ag Pulmonalno dajanje aminoglikozidov

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE78293T1 (de) * 1983-05-27 1992-08-15 Texas A & M Univ Sys Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
US4662514A (en) * 1983-11-01 1987-05-05 Charleswater Products, Inc. Electrically conductive polymeric tubes for static sensitive electronic devices
IL76082A (en) * 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
IE64006B1 (en) * 1984-10-18 1995-06-28 Pasteur Institut Antigens particulary envelope antigens of the virus of lymphadenopathies and of the acquired immune-deficiency syndrome and virus process for producing virus envelope antigens use of said antigens in the preparation of immunogenic compositions or for the diagnosis of the presence of antibodies against this virus
GB8501473D0 (en) * 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
DE3588134T2 (de) * 1984-12-24 1997-03-20 Genentech Inc Fusionen von AIDS-verwandten Polypeptiden
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
DK171119B1 (da) * 1985-04-19 1996-06-17 Hoffmann La Roche AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin
FR2586427B1 (fr) * 1985-08-20 1988-12-09 Pasteur Institut Sequences de nucleotides et de polypeptides issus du virus visna et leur application a des essais de diagnostic et a la production de compositions immunogenes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1105015C (zh) * 1995-09-06 2003-04-09 库夫施泰因模板技术股份公司 网板印刷模板的制备方法

Also Published As

Publication number Publication date
SE9102976L (sv) 1993-04-15
GB2181435A (en) 1987-04-23
IL80073A0 (en) 1986-12-31
SE9102975L (sv) 1993-04-15
IT8667730A0 (it) 1986-09-24
FR2587720B2 (cg-RX-API-DMAC10.html) 1995-02-10
SE9102976D0 (sv) 1991-10-14
MY103182A (en) 1993-05-29
IE59314B1 (en) 1994-02-09
YU46753B (sh) 1994-05-10
SE8604007L (sv) 1987-03-26
DE3690508T1 (cg-RX-API-DMAC10.html) 1988-06-23
WO1987002038A1 (en) 1987-04-09
HUT42133A (en) 1987-06-29
HU205780B (en) 1992-06-29
CN86106632A (zh) 1987-05-13
SE8604007D0 (sv) 1986-09-23
FR2587720A2 (fr) 1987-03-27
IE862525L (en) 1987-03-25
NO863803D0 (no) 1986-09-24
GB2181435B (en) 1990-01-10
IL80073A (en) 1995-01-24
FI863848L (fi) 1987-03-26
DK455486A (da) 1987-03-26
NO863803L (no) 1987-03-26
GR862412B (en) 1987-01-23
FI863848A7 (fi) 1987-03-26
SE9102974L (sv) 1993-04-15
DK455486D0 (da) 1986-09-24
SE9102975D0 (sv) 1991-10-14
FI863848A0 (fi) 1986-09-24
CH676247A5 (cg-RX-API-DMAC10.html) 1990-12-28
GB8622987D0 (en) 1986-10-29
ES2002490A6 (es) 1988-08-16
IT1195829B (it) 1988-10-27
ATA256786A (de) 1995-05-15
PT83434B (pt) 1988-07-29
NL8602422A (nl) 1987-04-16
YU165486A (en) 1989-08-31
ES2006941A6 (es) 1989-05-16
SE9102974D0 (sv) 1991-10-14
NZ217645A (en) 1991-11-26
PT83434A (en) 1986-10-01

Similar Documents

Publication Publication Date Title
CN1020752C (zh) 后天性免疫缺乏综合征(爱滋病)疫苗
US5833993A (en) Feline immunodeficiency virus vaccine
CN1229501C (zh) Hiv多包膜蛋白疫苗的重组痘苗载体混合物
US5420026A (en) Self-assembling replication defective hybrid virus particles
US20090297555A1 (en) Recombinant human cytomegalovirus and vaccines comprising heterologous antigens
JPH06508037A (ja) 免疫不全ウイルス組換えポックスウイルスワクチン
CN1067382A (zh) 人类乳头状瘤病毒肽的表达以及在致免疫组合物中的应用
CN101952436A (zh) 基于杆状病毒的疫苗
KR20230034933A (ko) Covid-19에 대한 보호를 위한 약독화된 폭스바이러스 벡터 기반 백신
JP2000506727A (ja) 組換え生ネコ免疫不全ウイルスおよびプロウイルスｄｎａワクチン
CN1068266A (zh) 人免疫缺陷病毒的疫苗及其治疗方法
JP2018019692A (ja) ワクチン接種目的のためのエプスタイン・バーウイルス由来の第二世代ウイルス様粒子（ｖｌｐ）
ES2198400T3 (es) Vector que codifica particulas virales no autopropagantes, defectuosas, auto-ensambladas.
CN87106696A (zh) 蛋白质及其制备方法，adn的顺序，抗体及其用途，痘病病毒，被转化或感染的细胞用于预防血吸虫病的药剂组合物，以及作为谷胱甘肽-s-转移酶活性的显示剂的用途
KR100347220B1 (ko) 재조합아데노바이러스hiv백신
Vlastos et al. VP1 pseudocapsids, but not a glutathione‐S‐transferase VP1 fusion protein, prevent polyomavirus infection in a T‐cell immune deficient experimental mouse model
PL181881B1 (pl) Wydzielona sekwencja DNA, wektor, transformowana komórka gospodarza, sposób wytwarzania bialka gp350, homogeniczne bialko gp350, srodek farmaceutyczny oraz kompozycja immunogenna PL PL PL PL PL PL PL PL PL
CN103946385B (zh) 作为对抗hiv-1的疫苗的嵌合非整合型慢病毒基因组
CN1054613A (zh) 一种在预防和治疗人体逆转录病毒中作为抗病毒剂和免疫原的非复制性的重组逆转录病毒颗粒
JPH02448A (ja) Ｈｉｖ−２ウィルスの蛋白質を発現させるためのベクターおよびその用途
CN1636013A (zh) 可编码hiv辅助蛋白的dna疫苗
CN1668736A (zh) 不含异源成分的gM－阴性EHV突变体
AU608205B2 (en) Vaccines against acquired immune deficiency syndrome
HK1081596A (en) gM-NEGATIVE EHV-MUTANTS WITHOUT HETEROLOGOUS ELEMENTS
Morello DNA vaccination against murine cytomegalovirus and the characterization of MCMV deletion mutants lacking the homologs of the human cytomegalovirus dominant cytotoxic T lymphocyte target UL83-pp65

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee